摘要
目的观察药物对非酒精性脂肪肝大鼠血浆和肝组织血栓素B2(TXB2)和6-酮-前列腺素F1α(6-Keto-PGFlα)的影响。方法高脂饲料制备Wistar大鼠非酒精性脂肪肝大鼠模型并用降脂益肝冲剂进行干预。苏木素-伊红(HE)染色观察肝脏病理组织学改变,放射免疫法测定血浆和肝组织TXB2和6-Keto-PGFlα含量及其比值。结果治疗组肝脏脂肪变性程度明显改善,6-Keto-PGFlα含量显著高于模型组(P<0.01),TXB2含量、TXB2/6-Keto-PGFlα比值明显低于模型组(P<0.01)。结论降脂益肝冲剂对大鼠血浆和肝组织TXB2、6-Keto-PGFlα的含量及其比值具有调节作用,这可能是其抗非酒精性脂肪肝的作用机制之一。
Objective To investigate the effect of medicine on plasma levels of TXB2 and 6-Keto-PGF1α in nonalcoholic fatty liver disease （NAFLD） rats. Methods The NAFLD Wistar rat model was established by high fat diet, and all the rats in the treatment group were intervened with Jiangzhiyigan Granula . Their pathologic changes were observed, and the amounts of plasma and liver TXB2 and 6-Keto-PGF1α ratio of them were detected with RIA. Results Hepatic steatosis of the treatment group was obviously improved,the amounts of plasma and liver 6-Keto-PGF1α were obviously higher than those in the model,the amounts of plasma and liver TXB2 and the ratio of TXB2/6-Keto-PGF1α were obviously lower than those in the model. Conclusion Jiangzhiyigan Granula may control the amounts of plasma and liver TXB2, 6-Keto-PGF1α and the ratio of TXB2/6-Keto-PGF1α, which may be the one of mechanisms of anti-nonalcoholic fatty liver disease.
